Last reviewed · How we verify
Triple-daily Insulin
Triple-daily insulin replaces or supplements the body's own insulin production to regulate blood glucose levels by facilitating glucose uptake into cells and promoting glycogen synthesis.
Triple-daily insulin replaces or supplements the body's own insulin production to regulate blood glucose levels by facilitating glucose uptake into cells and promoting glycogen synthesis. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient).
At a glance
| Generic name | Triple-daily Insulin |
|---|---|
| Sponsor | Hospital Universitario Dr. Jose E. Gonzalez |
| Drug class | Insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin is a peptide hormone that binds to insulin receptors on cell surfaces, enabling glucose transport into muscle, fat, and liver cells. By administering insulin three times daily, this regimen mimics the physiological pattern of endogenous insulin secretion to maintain glycemic control throughout the day and reduce postprandial and fasting hyperglycemia.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (when oral agents are insufficient)
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial (NA)
- Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes (PHASE4)
- Artificial Pancreas - Adolescent Physiology & Psychology Longitudinal Evaluation (NA)
- The Poor Responders Study (NA)
- New Triple Therapy in Newly Diagnosed Type 2 Diabetes (PHASE3)
- Triple Therapy in T1DM (PHASE2, PHASE3)
- The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients (PHASE4)
- Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triple-daily Insulin CI brief — competitive landscape report
- Triple-daily Insulin updates RSS · CI watch RSS
- Hospital Universitario Dr. Jose E. Gonzalez portfolio CI